COHERE patients with continuous or episodic viral suppression while on cART.

Note that the number of patients included in the main analyses of primary and secondary outcomes (n = 66,147) is lower than the number of patients in Tables 2–4 with at least one suppression episode (n = 75,336) because viral load prior to starting cART was not known for some patients.aNationality was not recorded for 40% of patients included in these analyses and for 50% of patients excluded from these analyses.bAt the start of a first suppression episode. Note that 103 patients that did not contribute a first episode to the main analyses because either no CD4 cell counts were available for this episode or this episode occurred while the patient was still under the age of 16.cLast viral load before starting combination therapy. Note that a further 4,211 patients did not contribute a first episode to the main analyses because their viral load before starting combination therapy was not known (although these patients contributed a first episode to the sensitivity analysis without this covariate).dOther: at least one protease inhibitor (PI) and one non-nucleoside reverse-transcriptase inhibitor (NNRTI), 5%; three NRTIs, 3%; at least two PIs (other than ritonavir) but no NNRTI, 2%; any therapy including integrase or fusion inhibitors, 1%.